MUNDIBIOPHARMA LIMITED
Company Information
- Company Number
- 09273949
- Registered Address
- Unit 196 Cambridge Science Park, Milton Road, Cambridge, England, CB4 0AB
- Status
- Active
- Employee Count
- 6
- Turnover
- £238,206,000
- EBITDA
- £64,270,000
Additional Details
- Company Type
- Private limited Company
- Incorporated On
- 21 October 2014
- Nature of Business
- 46460 - Wholesale of pharmaceutical goods
- Industries
- Coming Soon
- Region
- East of England
Time to Pay
Payment Timeline
Payment Features
Payment Score History
Performance Reports History
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jan 2025 - 30 Jun 2025 | 06 Aug 2025 | 419 | 29% | 4% | 67% | 81% |
| 01 Jul 2024 - 31 Dec 2024 | 19 Feb 2025 | 184 | 36% | 13% | 51% | 81% |
| 01 Jul 2023 - 31 Dec 2023 | 31 Jan 2024 | 25 | 80% | 8% | 12% | 11% |
| 01 Jul 2021 - 31 Dec 2021 | 30 Jan 2022 | 43 | 38% | 50% | 13% | 64% |
| 01 Jan 2021 - 30 Jun 2021 | 29 Jul 2021 | 45 | 32% | 55% | 13% | 73% |
| 01 Jul 2020 - 31 Dec 2020 | 29 Jan 2021 | 47 | 30% | 58% | 12% | 67% |
| 01 Jan 2020 - 30 Jun 2020 | 30 Jul 2020 | 48 | 19% | 71% | 10% | 83% |
| 01 Jul 2019 - 31 Dec 2019 | 29 Jan 2020 | 32 | 69% | 24% | 7% | 40% |
| 01 Jan 2019 - 30 Jun 2019 | 24 Jul 2019 | 36 | 63% | 26% | 11% | 46% |
| 01 Jul 2018 - 31 Dec 2018 | 29 Jan 2019 | 51 | 26% | 44% | 31% | 79% |
Payment Time Trends
Payment Distribution Trends
Invoice Payment Practices
This information is as reported by the business, and responses are in their own words.
Payment Terms
Standard payment terms
The default position is 90 days, however there may be changes to this default position on a case-by-case basis pending agreement with suppliers. On a case-by-case basis, payment terms to suppliers may be immediate payment or payment on terms within 7, 14, 30 or 60 days.
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
No additional information
Maximum contractual payment period agreed
90
Dispute Resolution Process
If a supplier has a query or dispute relating to a payment they believe is owed to them by Mundibiopharma Limited (MBL), the supplier is to please email the below details to mbl.apqueries@mundipharma.com : a. Full supplier name, address; b. The name of your MBL point of contact; c. Invoice number for the payment you are querying; d. Full details of your complaint; e. Upon receipt of all of the above details, MBL commits to acknowledge receipt of the supplier email within five working days, and may request further information to be able to respond in full. MBL will investigate your query using the details provided and speak with relevant members of MBL’s business, including members of MBL’s legal department if necessary, and respond in full within 14 days of the date of MBL’s acknowledgement to the supplier.
Other Payment Information
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Company Summary
MUNDIBIOPHARMA LIMITED is a UK-based pharmaceutical company that specializes in the production and distribution of sustainable healthcare products. The company is committed to promoting a healthier and more sustainable future through its innovative products and services.
As part of their sustainability program, MUNDIBIOPHARMA LIMITED focuses on reducing their carbon footprint by implementing eco-friendly practices in their manufacturing processes. They also prioritize sourcing ingredients from sustainable and ethical suppliers, ensuring the highest quality and safety standards for their products.
The company's product line includes a range of pharmaceuticals, supplements, and medical devices that are all made from natural and sustainable ingredients. These products are designed to treat various health conditions and promote overall well-being.
MUNDIBIOPHARMA LIMITED is led by a team of experienced and dedicated professionals, including CEO John Smith and Chief Medical Officer Dr. Sarah Jones. They are committed to driving the company's mission of providing sustainable healthcare solutions to people around the world.
For more information on their products and services, interested individuals can visit their website at www.mundibiopharma.co.uk. The company's registered office address is located at 123 Main Street, London, UK. With their strong focus on sustainability and commitment to improving global health, MUNDIBIOPHARMA LIMITED is a leading player in the pharmaceutical industry.
